Luke Dreher
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Luke Dreher has a total of 76 co-authors. Here are the top co-authors by number of shared publications:
- Hussein Abdul Nabi
Department of Cardiovascular Medicine, Mayo Clinic, 5777 East Mayo Blvd., Phoenix, AZ 85054, USA
12 shared publications - Fadi Elias Shamoun
Department of Cardiovascular Diseases, Mayo Clinic, Phoenix, AZ, USA
9 shared publications Chadi Ayoub
6 shared publications- Hicham El Masry
Department of Cardiovascular Medicine Mayo Clinic Phoenix Arizona USA
5 shared publications - Linnea M. Baudhuin
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA
5 shared publications - Mayowa Azeez Osundiji
Department of Clinical Genomics, Mayo Clinic, Phoenix, USA
5 shared publications
Latest Publications
- Open Access
- 9 November 2026
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 16 (11) , 576
Beyond the Aorta: Extra-Aortic Vascular Disease and Screening in Heritable and Systemic Arteriopathies
Heritable thoracic aortic disease (HTAD) comprises genetic disorders that predispose to thoracic aortic aneurysm and dissection. Several also affect arteries beyond the aorta. This narrative review examines the burden, distribution, mechanisms, and screening implications of extra-aortic vascular disease in vascular Ehlers–Danlos syndrome (vEDS), Loeys–Dietz syndrome (LDS), Marfan syndrome (MFS), and nonsyndromic HTAD, alongside the related systemic arteriopathies spontaneous coronary artery dissection (SCAD) and fibromuscular dysplasia (FMD). Disease- and genotype-specific patterns emerge, although estimates differ with referral patterns, imaging coverage, and outcome definitions. In the Montalcino Aortic Consortium (MAC), COL3A1 carriers had the highest proportion of extra-aortic clinical arterial events, with prominent abdominopelvic and cervical involvement. LDS showed widespread arterial disease and head and neck involvement. MFS had fewer clinical arterial events, but imaging studies identified branch aneurysms, particularly in patients with advanced aortic disease. SCAD and FMD frequently involved additional vascular territories. Findings from broader nonsyndromic thoracic aortic disease cohorts should be distinguished from genetically confirmed HTAD. Imaging-detected aneurysm prevalence and clinical event proportions are not interchangeable. Guidelines and consensus support disease-specific vascular assessment, but anatomical coverage, surveillance intervals, and evidence strength vary. Comprehensive baseline imaging is supported in LDS, FMD, and SCAD; European guidance also recommends peripheral surveillance in vEDS and MFS. Additional assessment in nonsyndromic HTAD and cervical artery dissection depends on genotype and clinical features. We outline a practical framework integrating the presenting vascular lesion, molecular diagnosis, prior events, family history, and imaging-related burden, and discuss when an extra-aortic presentation should prompt aortic evaluation. Prospective studies are needed to establish whether increased detection and changes in management improve patient-important outcomes.
- 9 November 2026
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 16 (11) , 576
Open AccessBeyond the Aorta: Extra-Aortic Vascular Disease and Screening in Heritable and Systemic Arteriopathies
Heritable thoracic aortic disease (HTAD) comprises genetic disorders that predispose to thoracic aortic aneurysm and dissection. Several also affect arteries beyond the aorta. This narrative review examines the burden, distribution, mechanisms, and screening implications of extra-aortic vascular disease in vascular Ehlers–Danlos syndrome (vEDS), Loeys–Dietz syndrome (LDS), Marfan syndrome (MFS), and nonsyndromic HTAD, alongside the related systemic arteriopathies spontaneous coronary artery dissection (SCAD) and fibromuscular dysplasia (FMD). Disease- and genotype-specific patterns emerge, although estimates differ with referral patterns, imaging coverage, and outcome definitions. In the Montalcino Aortic Consortium (MAC), COL3A1 carriers had the highest proportion of extra-aortic clinical arterial events, with prominent abdominopelvic and cervical involvement. LDS showed widespread arterial disease and head and neck involvement. MFS had fewer clinical arterial events, but imaging studies identified branch aneurysms, particularly in patients with advanced aortic disease. SCAD and FMD frequently involved additional vascular territories. Findings from broader nonsyndromic thoracic aortic disease cohorts should be distinguished from genetically confirmed HTAD. Imaging-detected aneurysm prevalence and clinical event proportions are not interchangeable. Guidelines and consensus support disease-specific vascular assessment, but anatomical coverage, surveillance intervals, and evidence strength vary. Comprehensive baseline imaging is supported in LDS, FMD, and SCAD; European guidance also recommends peripheral surveillance in vEDS and MFS. Additional assessment in nonsyndromic HTAD and cervical artery dissection depends on genotype and clinical features. We outline a practical framework integrating the presenting vascular lesion, molecular diagnosis, prior events, family history, and imaging-related burden, and discuss when an extra-aortic presentation should prompt aortic evaluation. Prospective studies are needed to establish whether increased detection and changes in management improve patient-important outcomes.
- 1 November 2026
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 19 (11)
Ventricular Arrhythmias in Marfan Syndrome: Prevalence and Clinical Correlates in a Multicenter Cohort
BACKGROUND: Ventricular arrhythmias are increasingly recognized in Marfan syndrome, but associated clinical and structural features remain incompletely defined. METHODS: We performed a retrospective multicenter cohort study of 783 adults with confirmed Marfan syndrome at 3 Mayo Clinic sites. Clinical, arrhythmic, echocardiographic, cardiac magnetic resonance, surgical, and implantable cardioverter defibrillator data were obtained by manual chart review. Associations with sustained ventricular tachycardia (VT) or ventricular fibrillation (VF) were evaluated using univariable logistic regression, a primary multivariable model in the full cohort, and a prespecified exploratory cardiac magnetic resonance sensitivity model. RESULTS: Sustained VT/VF occurred in 74 patients (9.5%) over 12.7±7.6 years. On univariable analysis, sustained VT/VF clustered with an adverse structural-electrical phenotype including atrial arrhythmias, ventricular remodeling, mitral valve disease, cardiac surgery history, and late gadolinium enhancement. In the primary multivariable model, nonsustained VT (odds ratio, 12.11 [95% CI, 6.43–22.79]; P P P =0.001), and moderate-severe mitral regurgitation (odds ratio, 2.00 [95% CI, 1.07–3.75]; P =0.030) were independently associated with sustained VT/VF. In the cardiac magnetic resonance sensitivity model, nonsustained VT, lower left ventricular ejection fraction, and late gadolinium enhancement remained associated with sustained VT/VF. CONCLUSIONS: In adults with Marfan syndrome, sustained VT/VF occurs in nearly 1 in 10 patients and is associated with a broader structural-electrical phenotype. Late gadolinium enhancement provided additional risk signal among patients undergoing cardiac magnetic resonance.
- 1 November 2026
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 19 (11)
Ventricular Arrhythmias in Marfan Syndrome: Prevalence and Clinical Correlates in a Multicenter Cohort
BACKGROUND: Ventricular arrhythmias are increasingly recognized in Marfan syndrome, but associated clinical and structural features remain incompletely defined. METHODS: We performed a retrospective multicenter cohort study of 783 adults with confirmed Marfan syndrome at 3 Mayo Clinic sites. Clinical, arrhythmic, echocardiographic, cardiac magnetic resonance, surgical, and implantable cardioverter defibrillator data were obtained by manual chart review. Associations with sustained ventricular tachycardia (VT) or ventricular fibrillation (VF) were evaluated using univariable logistic regression, a primary multivariable model in the full cohort, and a prespecified exploratory cardiac magnetic resonance sensitivity model. RESULTS: Sustained VT/VF occurred in 74 patients (9.5%) over 12.7±7.6 years. On univariable analysis, sustained VT/VF clustered with an adverse structural-electrical phenotype including atrial arrhythmias, ventricular remodeling, mitral valve disease, cardiac surgery history, and late gadolinium enhancement. In the primary multivariable model, nonsustained VT (odds ratio, 12.11 [95% CI, 6.43–22.79]; P P P =0.001), and moderate-severe mitral regurgitation (odds ratio, 2.00 [95% CI, 1.07–3.75]; P =0.030) were independently associated with sustained VT/VF. In the cardiac magnetic resonance sensitivity model, nonsustained VT, lower left ventricular ejection fraction, and late gadolinium enhancement remained associated with sustained VT/VF. CONCLUSIONS: In adults with Marfan syndrome, sustained VT/VF occurs in nearly 1 in 10 patients and is associated with a broader structural-electrical phenotype. Late gadolinium enhancement provided additional risk signal among patients undergoing cardiac magnetic resonance.
- Open Access
- 23 October 2026
- Published by Elsevier in Heart Rhythm O2
Cardiac magnetic resonance scar burden and appropriate defibrillator therapy in cardiac sarcoidosis
- 23 October 2026
- Published by Elsevier in Heart Rhythm O2
Open AccessCardiac magnetic resonance scar burden and appropriate defibrillator therapy in cardiac sarcoidosis
- Open Access
- 30 July 2026
- Published by Elsevier in Heart Rhythm O2
Predictors of appropriate implantable cardioverter-defibrillator therapy in noncompaction cardiomyopathy
- 30 July 2026
- Published by Elsevier in Heart Rhythm O2
Open AccessPredictors of appropriate implantable cardioverter-defibrillator therapy in noncompaction cardiomyopathy
- Open Access
- 20 July 2026
- Published by Elsevier in JACC: Advances
- Vol. 5 (8)
Sex-Specific Cardiovascular Phenotypes in Marfan Syndrome
- 20 July 2026
- Published by Elsevier in JACC: Advances
- Vol. 5 (8)
Open AccessSex-Specific Cardiovascular Phenotypes in Marfan Syndrome
- Open Access
- 7 July 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (13) , 5302
Prevalence, Predictors, and Clinical Outcomes of Cervical Arterial Dissection in Patients with Spontaneous Coronary Artery Dissection: A Multicenter Retrospective Cohort Study
Background: Patients with spontaneous coronary artery dissection (SCAD) are at increased risk of cardiovascular events, including dissection in other arterial territories such as cervical arteries. Those with combined coronary and cervical arterial dissection (CACAD) may have more widespread arterial abnormalities and worse outcomes, underscoring the need for better risk stratification and personalized care. Objective: This study examined the prevalence of cervical artery dissection (CvAD) in patients diagnosed with SCAD, evaluated potential risk factors for developing CvAD, and assessed their impact on clinical outcomes, including all-cause mortality, SCAD recurrence, and stroke. The goal was to enhance risk stratification by identifying SCAD patients at increased risk for CvAD. Design: In this retrospective cohort study, patients diagnosed with SCAD between 2018 and 2024 across Mayo Clinic sites were identified using ICD-10 codes. Manual chart review confirmed CvAD diagnoses. Patients were stratified based on the presence or absence of CvAD. Chi-square and independent t-tests were used to compare risk factors and comorbidities. Univariate screening and multivariable logistic regression were used to identify predictors of CvAD. Results: Among 1380 patients with SCAD, 131 (9.5%) had CvAD. The median follow-up was 2.02 years (IQR: 1.1–5.2 years). All CvAD diagnoses were identified after the index SCAD event through systematic post-SCAD vascular imaging. The mean age was similar between groups (51.5 ± 11.3 years in CACAD vs. 50.9 ± 10.7 years in SCAD-only, p = 0.540), and the majority were female (93.9% vs. 91.9%, p = 0.529). Multivariable regression identified extremity arterial dissection (OR: 8.13, 95% CI: 3.41–19.36, p < 0.001), fibromuscular dysplasia (FMD) (OR: 7.52, 95% CI: 4.67–12.10, p < 0.001), connective tissue disorders (CTDs) (OR: 6.85, 95% CI: 2.35–19.98, p < 0.001), and anxiety (OR: 1.69, 95% CI: 1.01–2.81, p = 0.044) as significant predictors of CvAD. CvAD was a strong independent predictor of stroke (OR: 6.37, 95% CI: 2.93–13.87, p < 0.001). Mortality and SCAD recurrence did not differ significantly between groups. Conclusions: Patients with CACAD demonstrate a systemic vascular phenotype with significantly higher rates of FMD, connective tissue disease, extremity arterial dissection, and stroke. These findings highlight the importance of comprehensive vascular screening and individualized monitoring in at-risk SCAD patients.
- 7 July 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (13) , 5302
Open AccessPrevalence, Predictors, and Clinical Outcomes of Cervical Arterial Dissection in Patients with Spontaneous Coronary Artery Dissection: A Multicenter Retrospective Cohort Study
Background: Patients with spontaneous coronary artery dissection (SCAD) are at increased risk of cardiovascular events, including dissection in other arterial territories such as cervical arteries. Those with combined coronary and cervical arterial dissection (CACAD) may have more widespread arterial abnormalities and worse outcomes, underscoring the need for better risk stratification and personalized care. Objective: This study examined the prevalence of cervical artery dissection (CvAD) in patients diagnosed with SCAD, evaluated potential risk factors for developing CvAD, and assessed their impact on clinical outcomes, including all-cause mortality, SCAD recurrence, and stroke. The goal was to enhance risk stratification by identifying SCAD patients at increased risk for CvAD. Design: In this retrospective cohort study, patients diagnosed with SCAD between 2018 and 2024 across Mayo Clinic sites were identified using ICD-10 codes. Manual chart review confirmed CvAD diagnoses. Patients were stratified based on the presence or absence of CvAD. Chi-square and independent t-tests were used to compare risk factors and comorbidities. Univariate screening and multivariable logistic regression were used to identify predictors of CvAD. Results: Among 1380 patients with SCAD, 131 (9.5%) had CvAD. The median follow-up was 2.02 years (IQR: 1.1–5.2 years). All CvAD diagnoses were identified after the index SCAD event through systematic post-SCAD vascular imaging. The mean age was similar between groups (51.5 ± 11.3 years in CACAD vs. 50.9 ± 10.7 years in SCAD-only, p = 0.540), and the majority were female (93.9% vs. 91.9%, p = 0.529). Multivariable regression identified extremity arterial dissection (OR: 8.13, 95% CI: 3.41–19.36, p < 0.001), fibromuscular dysplasia (FMD) (OR: 7.52, 95% CI: 4.67–12.10, p < 0.001), connective tissue disorders (CTDs) (OR: 6.85, 95% CI: 2.35–19.98, p < 0.001), and anxiety (OR: 1.69, 95% CI: 1.01–2.81, p = 0.044) as significant predictors of CvAD. CvAD was a strong independent predictor of stroke (OR: 6.37, 95% CI: 2.93–13.87, p < 0.001). Mortality and SCAD recurrence did not differ significantly between groups. Conclusions: Patients with CACAD demonstrate a systemic vascular phenotype with significantly higher rates of FMD, connective tissue disease, extremity arterial dissection, and stroke. These findings highlight the importance of comprehensive vascular screening and individualized monitoring in at-risk SCAD patients.
- Open Access
- 1 July 2026
- Published by BMJ in Open Heart
- Vol. 13 (2) , e004552
Sex-associated territory-specific vascular phenotypes in genetically confirmed vascular Ehlers-Danlos syndrome
- 1 July 2026
- Published by BMJ in Open Heart
- Vol. 13 (2) , e004552
Open AccessSex-associated territory-specific vascular phenotypes in genetically confirmed vascular Ehlers-Danlos syndrome
- Open Access
- 18 June 2026
- Published by MDPI AG in Medical Sciences
- Vol. 14 (2) , 329
Cardiometabolic and RAAS-Targeted Therapy in Thoracic Aortic Aneurysm: Propensity-Matched Associations with Survival and Major Cardiovascular Events
Background: Thoracic aortic aneurysm (TAA) remains a high-risk vascular condition despite major advances in imaging surveillance, operative repair, and endovascular therapy. Medical management still relies largely on blood pressure control and global cardiovascular risk reduction. Renin–angiotensin–aldosterone system (RAAS) inhibitors are frequently used in TAA, but contemporary data evaluating survival and cardiovascular outcomes in broad TAA populations are limited. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) have established cardiometabolic benefits, yet their role in TAA has not been well defined. Methods: We performed a retrospective multicenter cohort study of adults with imaging-confirmed TAA diagnosed between 1 January 2018 and 1 January 2026 using a Mayo Clinic electronic data platform encompassing more than 15 million patient records. Primary exposures were documented use of RAAS inhibitors, GLP-1 RAs, and SGLT2 inhibitors, evaluated individually and in prespecified combination-therapy analyses. Propensity score matching was used to balance demographics, comorbidities, aortic procedural history, and concomitant cardiovascular medications. Primary outcomes were all-cause mortality and major adverse cardiovascular events (MACE) through 60 months. Results: The study included 162,126 patients with TAA. After matching, RAAS inhibitor use was associated with higher 60-month overall survival (88.3% vs. 85.5%; hazard ratio [HR], 0.79; 95% CI, 0.76–0.83; p < 0.001) and MACE-free survival (86.1% vs. 84.2%; HR, 0.87; 95% CI, 0.83–0.91; p < 0.001). GLP-1 RA therapy was associated with higher overall survival (97.5% vs. 92.5%; HR, 0.32; 95% CI, 0.27–0.38; p < 0.001) and MACE-free survival (93.2% vs. 89.3%; HR, 0.62; 95% CI, 0.56–0.70; p < 0.001). SGLT2 inhibitor therapy was similarly associated with higher overall survival (89.8% vs. 81.5%; HR, 0.51; 95% CI, 0.47–0.54; p < 0.001) and MACE-free survival (86.3% vs. 79.1%; HR, 0.62; 95% CI, 0.58–0.66; p < 0.001). Combination therapy with RAAS inhibitors plus either GLP-1 RAs or SGLT2 inhibitors was associated with incremental improvements in overall survival and MACE-free survival compared with GLP-1 RA or SGLT2 inhibitor monotherapy. Conclusions: In this large propensity-matched TAA cohort, RAAS inhibitors, GLP-1 RAs, and SGLT2 inhibitors were each associated with improved survival and fewer major cardiovascular events, with additional benefit observed for RAAS-based combination therapy. These findings support further prospective investigation of integrated cardiometabolic and vascular-targeted therapy in TAA, while underscoring that observational associations should not be interpreted as proof of aneurysm-specific disease modification.
- 18 June 2026
- Published by MDPI AG in Medical Sciences
- Vol. 14 (2) , 329
Open AccessCardiometabolic and RAAS-Targeted Therapy in Thoracic Aortic Aneurysm: Propensity-Matched Associations with Survival and Major Cardiovascular Events
Background: Thoracic aortic aneurysm (TAA) remains a high-risk vascular condition despite major advances in imaging surveillance, operative repair, and endovascular therapy. Medical management still relies largely on blood pressure control and global cardiovascular risk reduction. Renin–angiotensin–aldosterone system (RAAS) inhibitors are frequently used in TAA, but contemporary data evaluating survival and cardiovascular outcomes in broad TAA populations are limited. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) have established cardiometabolic benefits, yet their role in TAA has not been well defined. Methods: We performed a retrospective multicenter cohort study of adults with imaging-confirmed TAA diagnosed between 1 January 2018 and 1 January 2026 using a Mayo Clinic electronic data platform encompassing more than 15 million patient records. Primary exposures were documented use of RAAS inhibitors, GLP-1 RAs, and SGLT2 inhibitors, evaluated individually and in prespecified combination-therapy analyses. Propensity score matching was used to balance demographics, comorbidities, aortic procedural history, and concomitant cardiovascular medications. Primary outcomes were all-cause mortality and major adverse cardiovascular events (MACE) through 60 months. Results: The study included 162,126 patients with TAA. After matching, RAAS inhibitor use was associated with higher 60-month overall survival (88.3% vs. 85.5%; hazard ratio [HR], 0.79; 95% CI, 0.76–0.83; p < 0.001) and MACE-free survival (86.1% vs. 84.2%; HR, 0.87; 95% CI, 0.83–0.91; p < 0.001). GLP-1 RA therapy was associated with higher overall survival (97.5% vs. 92.5%; HR, 0.32; 95% CI, 0.27–0.38; p < 0.001) and MACE-free survival (93.2% vs. 89.3%; HR, 0.62; 95% CI, 0.56–0.70; p < 0.001). SGLT2 inhibitor therapy was similarly associated with higher overall survival (89.8% vs. 81.5%; HR, 0.51; 95% CI, 0.47–0.54; p < 0.001) and MACE-free survival (86.3% vs. 79.1%; HR, 0.62; 95% CI, 0.58–0.66; p < 0.001). Combination therapy with RAAS inhibitors plus either GLP-1 RAs or SGLT2 inhibitors was associated with incremental improvements in overall survival and MACE-free survival compared with GLP-1 RA or SGLT2 inhibitor monotherapy. Conclusions: In this large propensity-matched TAA cohort, RAAS inhibitors, GLP-1 RAs, and SGLT2 inhibitors were each associated with improved survival and fewer major cardiovascular events, with additional benefit observed for RAAS-based combination therapy. These findings support further prospective investigation of integrated cardiometabolic and vascular-targeted therapy in TAA, while underscoring that observational associations should not be interpreted as proof of aneurysm-specific disease modification.
- Open Access
- 11 June 2026
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 13 (6) , 259
Atrial Fibrillation in Cardiac Amyloidosis: A Multicenter Experience Comparing Novel Oral Anticoagulants and Warfarin
Background: AF in the setting of cardiac amyloidosis is associated with a high risk of TEs, irrespective of CHA2DS2-VASc score. While warfarin has been the traditional anticoagulant, DOACs offer a promising alternative, but their safety in this population remains underexplored. This study aimed to evaluate the prevalence of thromboembolic events (TEs), including stroke and transient ischemic attack (TIA), and major bleeding events in patients with cardiac amyloidosis (CA) and atrial fibrillation (AF) treated with either warfarin or direct oral anticoagulants (DOACs). Additionally, we aimed to explore whether DOACs are at least as effective as warfarin in protecting against TEs in this population. Methods: This retrospective cohort study analyzed 422 patients with confirmed CA and AF from Mayo Clinic, with a median follow-up of 4.3 years. Data on anticoagulation therapy, baseline characteristics, and outcomes (TEs and bleeding) were collected. Statistical analyses included chi-square tests, t-tests, and Cox regression to assess the relationship between anticoagulation and TE. Results: Among 422 patients, 21 experienced a TE. The annual event rate was 0.83% for warfarin and 0.67% for DOACs, with no significant difference (HR 0.66, CI 0.22–2.01, p = 0.5). Patients with anticoagulation interruptions > 5 days had increased TE risk (HR 3.19, CI 0.97–10.5, p = 0.056). The bleeding rate was 9.9% over 4.3 years (2.33% per year), with no significant differences between anticoagulants. Conclusions: Both warfarin and DOACs have similar, low risks of TEs in CA and AF patients. However, anticoagulation interruptions were associated with increased TE risk, emphasizing the challenges in managing anticoagulation in this population.
- 11 June 2026
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 13 (6) , 259
Open AccessAtrial Fibrillation in Cardiac Amyloidosis: A Multicenter Experience Comparing Novel Oral Anticoagulants and Warfarin
Background: AF in the setting of cardiac amyloidosis is associated with a high risk of TEs, irrespective of CHA2DS2-VASc score. While warfarin has been the traditional anticoagulant, DOACs offer a promising alternative, but their safety in this population remains underexplored. This study aimed to evaluate the prevalence of thromboembolic events (TEs), including stroke and transient ischemic attack (TIA), and major bleeding events in patients with cardiac amyloidosis (CA) and atrial fibrillation (AF) treated with either warfarin or direct oral anticoagulants (DOACs). Additionally, we aimed to explore whether DOACs are at least as effective as warfarin in protecting against TEs in this population. Methods: This retrospective cohort study analyzed 422 patients with confirmed CA and AF from Mayo Clinic, with a median follow-up of 4.3 years. Data on anticoagulation therapy, baseline characteristics, and outcomes (TEs and bleeding) were collected. Statistical analyses included chi-square tests, t-tests, and Cox regression to assess the relationship between anticoagulation and TE. Results: Among 422 patients, 21 experienced a TE. The annual event rate was 0.83% for warfarin and 0.67% for DOACs, with no significant difference (HR 0.66, CI 0.22–2.01, p = 0.5). Patients with anticoagulation interruptions > 5 days had increased TE risk (HR 3.19, CI 0.97–10.5, p = 0.056). The bleeding rate was 9.9% over 4.3 years (2.33% per year), with no significant differences between anticoagulants. Conclusions: Both warfarin and DOACs have similar, low risks of TEs in CA and AF patients. However, anticoagulation interruptions were associated with increased TE risk, emphasizing the challenges in managing anticoagulation in this population.
- Open Access
- 5 June 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (11) , 1742
The Association Between Glucagon-like Peptide-1 Receptor Agonists and Clinical Outcomes in Patients with Thoracic Aortic Aneurysm
Background/Objectives: Thoracic aortic aneurysm (TAA) often results from structural degeneration of the aortic wall. Traditional management focuses on hemodynamic control using beta-blockers (BB) and angiotensin receptor blockers (ARBs). Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), originally developed for diabetes and weight management, may offer additional vascular protective benefits through anti-inflammatory, antioxidative, and matrix-stabilizing mechanisms. However, their role in reducing mortality and thoracic aortic dissection (TAD) risk in patients with TAA has not been evaluated in human populations. In this study, we aimed to assess the association between GLP-1 RA use and the risks of mortality and thoracic aortic dissection. Methods: We conducted a retrospective cohort study of adults diagnosed with TAA between 2018 and 2024 across three Mayo Clinic sites. Patients receiving GLP-1 RAs were compared with non-users using 1:1 propensity score matching. Outcomes included all-cause mortality, cardiovascular mortality, and incident TAD. Kaplan–Meier and Cox proportional hazards analyses were performed. Results: A total of 32,279 patients with TAA, with a median age of 68.0 [IQR: 59.0–76.0] and 70.7% male, were included in a 1:1 propensity score match. This yielded a balanced cohort of 588 GLP-1 RA users and 588 non-users. Through a median follow-up of 4.1 (2.2, 5.9) years, GLP-1 RA use was associated with significantly lower 5-year cumulative incidence of all-cause mortality (5.0% vs. 14.5%, HR: 0.31; 95% CI: 0.19–0.50; p < 0.001), cardiovascular mortality (1.9% vs. 5.5%, HR: 0.30; 95% CI: 0.13–0.70; p = 0.005), and TAD (0.9% vs. 4.0%, HR: 0.19; 95% CI: 0.06–0.60; p < 0.0004). Conclusions: GLP-1 RAs are associated with reduced incidence of all-cause mortality, cardiovascular mortality, and TAD incidence in patients with TAA. Prospective studies are needed to confirm these findings and evaluate effects on aneurysm progression.
- 5 June 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (11) , 1742
Open AccessThe Association Between Glucagon-like Peptide-1 Receptor Agonists and Clinical Outcomes in Patients with Thoracic Aortic Aneurysm
Background/Objectives: Thoracic aortic aneurysm (TAA) often results from structural degeneration of the aortic wall. Traditional management focuses on hemodynamic control using beta-blockers (BB) and angiotensin receptor blockers (ARBs). Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), originally developed for diabetes and weight management, may offer additional vascular protective benefits through anti-inflammatory, antioxidative, and matrix-stabilizing mechanisms. However, their role in reducing mortality and thoracic aortic dissection (TAD) risk in patients with TAA has not been evaluated in human populations. In this study, we aimed to assess the association between GLP-1 RA use and the risks of mortality and thoracic aortic dissection. Methods: We conducted a retrospective cohort study of adults diagnosed with TAA between 2018 and 2024 across three Mayo Clinic sites. Patients receiving GLP-1 RAs were compared with non-users using 1:1 propensity score matching. Outcomes included all-cause mortality, cardiovascular mortality, and incident TAD. Kaplan–Meier and Cox proportional hazards analyses were performed. Results: A total of 32,279 patients with TAA, with a median age of 68.0 [IQR: 59.0–76.0] and 70.7% male, were included in a 1:1 propensity score match. This yielded a balanced cohort of 588 GLP-1 RA users and 588 non-users. Through a median follow-up of 4.1 (2.2, 5.9) years, GLP-1 RA use was associated with significantly lower 5-year cumulative incidence of all-cause mortality (5.0% vs. 14.5%, HR: 0.31; 95% CI: 0.19–0.50; p < 0.001), cardiovascular mortality (1.9% vs. 5.5%, HR: 0.30; 95% CI: 0.13–0.70; p = 0.005), and TAD (0.9% vs. 4.0%, HR: 0.19; 95% CI: 0.06–0.60; p < 0.0004). Conclusions: GLP-1 RAs are associated with reduced incidence of all-cause mortality, cardiovascular mortality, and TAD incidence in patients with TAA. Prospective studies are needed to confirm these findings and evaluate effects on aneurysm progression.